The Transition From Hypertension to Heart Failure: Contemporary Update

JACC: Heart Failure

Volumn 5, Issue 8, 2017, Pages 543-551

  Messerli, Franz H ^a,b,c   Rimoldi, Stefano F ^a   Bangalore, Sripal ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antihypertensive therapy; cardiorenal syndrome; HFpEF; hypertensive heart disease; left ventricular hypertrophy; Pickering syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; INDAPAMIDE; IVABRADINE; NEBIVOLOL; PLACEBO; SACUBITRIL PLUS VALSARTAN;

BLOOD PRESSURE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIORENAL SYNDROME; CONGESTIVE CARDIOMYOPATHY; DECAPITATED HYPERTENSION; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY ARTERY; KIDNEY FAILURE; LUNG EDEMA; PATHOPHYSIOLOGY; PICKERING SYNDROME; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVASCULARIZATION; REVIEW; CHRONIC DISEASE; COMPLICATION; HEART LEFT VENTRICLE FUNCTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIO-RENAL SYNDROME; CHRONIC DISEASE; HEART FAILURE; HUMANS; HYPERTENSION; PULMONARY EDEMA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85023603604     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.04.012     Document Type: Review

References (42)

1. Levy, D., Larson, M.G., Vasan, R.S., Kannel, W.B., Ho, K.K., The progression from hypertension to congestive heart failure. JAMA 275 (1996), 1557–1562.
2. Lloyd-Jones, D.M., Larson, M.G., Leip, E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002), 3068–3072.
3. Ahmad, F.S., Ning, H., Rich, J.D., Yancy, C.W., Lloyd-Jones, D.M., Wilkins, J.T., Hypertension, obesity, diabetes, and heart failure-free survival: the Cardiovascular Disease Lifetime Risk Pooling Project. J Am Coll Cardiol HF 4 (2016), 911–919.
4. Kostis, J.B., Cabrera, J., Cheng, J.Q., et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 306 (2011), 2588–2593.
5. Messerli, F.H., Cardiovascular effects of obesity and hypertension. Lancet 1 (1982), 1165–1168.
6. Seliger, S.L., de Lemos, J., Neeland, I.J., et al. Older adults, “malignant” left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). J Am Coll Cardiol HF 3 (2015), 445–455.
7. Iriarte, M., Murga, N., Sagastagoitia, D., et al. Classification of hypertensive cardiomyopathy. Eur Heart J 14:Suppl J (1993), 95–101.
8. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
9. Mohammed, S.F., Hussain, S., Mirzoyev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
10. Gandhi, S.K., Powers, J.C., Nomeir, A.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344 (2001), 17–22.
11. Oakley, C., Diagnosis and natural history of congested (dilated) cardiomyopathies. Postgrad Med J 54 (1978), 440–450.
12. Ather, S., Bangalore, S., Vemuri, S., Cao, L.B., Bozkurt, B., Messerli, F.H., Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. Am J Cardiol 107 (2011), 561–568.
13. Tanaka, Y., Tada, H., Yamashita, E., et al. Change in blood pressure just after initiation of cardiac resynchronization therapy predicts long-term clinical outcome in patients with advanced heart failure. Circ J 73 (2009), 288–294.
14. Adamopoulos, C., Zannad, F., Fay, R., et al. Ejection fraction and blood pressure are important and interactive predictors of 4-week mortality in severe acute heart failure. Eur J Heart Fail 9 (2007), 935–941.
15. Bhatia, R.S., Tu, J.V., Lee, D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
16. Fonarow, G.C., Adams, K.F. Jr., Abraham, W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005), 572–580.
17. Gheorghiade, M., Abraham, W.T., Albert, N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006), 2217–2226.
18. Lee, T.T., Chen, J., Cohen, D.J., Tsao, L., The association between blood pressure and mortality in patients with heart failure. Am Heart J 151 (2006), 76–83.
19. Pulignano, G., Del Sindaco, D., Tavazzi, L., et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 143 (2002), 45–55.
20. Schrier, R.W., Abraham, W.T., Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999), 577–585.
21. Rouleau, J.L., Roecker, E.B., Tendera, M., et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 43 (2004), 1423–1429.
22. McAlister, F.A., Wiebe, N., Ezekowitz, J.A., Leung, A.A., Armstrong, P.W., Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 (2009), 784–794.
23. Swedberg, K., Komajda, M., Bohm, M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
24. Rimoldi, S.F., Messerli, F.H., Cerny, D., et al. Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease. Hypertension 67 (2016), 1205–1210.
25. Messerli, F.H., Rimoldi, S.F., Bangalore, S., Bavishi, C., Laurent, S., When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol 68 (2016), 754–762.
26. Bock, J.S., Gottlieb, S.S., Cardiorenal syndrome: new perspectives. Circulation 121 (2010), 2592–2600.
27. Ronco, C., Cicoira, M., McCullough, P.A., Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60 (2012), 1031–1042.
28. Epstein, M., Pitt, B.C., A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'. Eur Heart J 37 (2016), 3130–3134.
29. Pickering, T.G., Herman, L., Devereux, R.B., et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 2 (1988), 551–552.
30. Messerli, F.H., Bangalore, S., Makani, H., et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 32 (2011), 2231–2235.
31. Rimoldi, S.F., Yuzefpolskaya, M., Allemann, Y., Messerli, F., Flash pulmonary edema. Prog Cardiovasc Dis 52 (2009), 249–259.
32. Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47 (2006), 1239–1312.
33. Kotecha, D., Manzano, L., Krum, H., et al. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, 353, 2016, i1855.
34. Bangalore, S., Wild, D., Parkar, S., Kukin, M., Messerli, F.H., Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 52 (2008), 1062–1072.
35. Chen, N., Zhou, M., Yang, M., et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev, 8, 2010, CD003654.
36. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure-lowering treatment: 6. Prevention of heart failure and new-onset heart failure–meta-analyses of randomized trials. J Hypertens 34 (2016), 373–384 discussion 384.
37. Bangalore, S., Fakheri, R., Toklu, B., Ogedegbe, G., Weintraub, H., Messerli, F.H., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clinic Proc 91 (2016), 51–60.
38. Messerli, F.H., Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation 135 (2017), 2085–2087.
39. Bavishi, C., Messerli, F.H., Kadosh, B., Ruilope, L.M., Kario, K., Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 36 (2015), 1967–1973.
40. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
41. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 (1991), 3255–3264.
42. Beckett, N.S., Peters, R., Fletcher, A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898.